Docetaxel vs non‐docetaxel‐containing regimens: Tumour response
Docetaxel probably leads to higher tumour response compared with non‐docetaxel‐containing regimens (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Docetaxel vs non‐docetaxel‐containing regimens Tumour response · people with advanced gastric cancer Docetaxel probably leads to higher tumour response compared with non‐docetaxel‐containing regimens (moderate certainty). Chemotherapy for advanced gastric cancer (2017) · Cochrane Headline outcomes only | OR 1.37 [1.03, 1.83] | 9 studies · 1820 participants | Moderate |
Docetaxel vs non‐docetaxel‐containing regimens Tumour response ‐ Substitutive comparison · people with advanced gastric cancer Docetaxel showed no clear difference in tumour response ‐ Substitutive comparison compared with non‐docetaxel‐containing regimens (moderate certainty). Chemotherapy for advanced gastric cancer (2017) · Cochrane Headline outcomes only | OR 1.03 [0.71, 1.5] | 4 studies · 525 participants | Moderate |
Docetaxel vs non‐docetaxel‐containing regimens Tumour response ‐ Additive comparison · people with advanced gastric cancer Docetaxel leads to higher tumour response ‐ Additive comparison compared with non‐docetaxel‐containing regimens (high certainty). Chemotherapy for advanced gastric cancer (2017) · Cochrane Headline outcomes only | OR 1.83 [1.45, 2.32] | 4 studies · 1235 participants | High |
Docetaxel vs non‐docetaxel‐containing regimens Tumour response ‐ Other comparison · people with advanced gastric cancer It is very uncertain whether docetaxel changes tumour response ‐ Other comparison compared with non‐docetaxel‐containing regimens (very low certainty). Chemotherapy for advanced gastric cancer (2017) · Cochrane Headline outcomes only | OR 0.33 [0.12, 0.96] | 1 study · 60 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.